Potential of anti-Candida antibodies in immunoprophylaxis

Immunotherapy
Jonathan CabezasJosé Pontón

Abstract

The need for new options for the treatment of invasive candidiasis has fuelled the use of antibodies in combination with conventional antifungal therapy. After a long period of time in which antibodies were considered irrelevant in the resistance against invasive candidiasis, it was demonstrated that a number of antibodies or their engineered derivatives directed against Candida albicans cell-wall polysaccharides and glycopeptides, as well as against some protein epitopes, confer protection against invasive candidiasis. This has confirmed this approach as a new strategy for the prophylaxis of invasive candidiasis. Of particular interest is Mycograb, a human recombinant monoclonal antibody that inhibits heat shock protein 90, and has been administrated in combination with lipid-associated amphotericin B to patients with invasive candidiasis, and the fungicidal anti-beta-glucan antibodies induced by the glycoconjugate vaccine composed of a beta-glucan polysaccharide conjugated with the diphtheria toxoid CRM 197. However, despite the promising data obtained in vitro and in animal models, at present there is very little clinical experience on the use of antibodies in Candida immunoprophylaxis.

References

Mar 1, 1976·Sabouraudia·S F Grappel, R A Calderone
Nov 1, 1992·Infection and Immunity·J MukherjeeA Casadevall
Jul 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A Casadevall, M D Scharff
Jul 1, 1995·Infection and Immunity·Y Han, J E Cutler
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J MukherjeeA Casadevall
Mar 1, 1997·Clinical and Diagnostic Laboratory Immunology·L PolonelliJ C Cailliez
Jul 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·Y HanJ E Cutler
Feb 21, 2002·Infection and Immunity·Francis GigliottiAllen G Harmsen
Jan 7, 2003·Infectious Disease Clinics of North America·Luis Ostrosky-ZeichnerBart-Jan Kullberg
Apr 26, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Jun 25, 2003·Antimicrobial Agents and Chemotherapy·Ruth C MatthewsJames Burnie
Oct 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Olafur GudlaugssonDaniel Diekema
Oct 17, 2003·The Journal of Clinical Investigation·Joshua D NosanchukArturo Casadevall
Nov 1, 2003·The Lancet Infectious Diseases·Philippe EggimannDidier Pittet
Jan 17, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Oscar MarchettiUNKNOWN Fungal Infection Network of Switzerland
Sep 28, 2004·The Journal of Antimicrobial Chemotherapy·Luiz R TravassosLuciano Polonelli
Oct 27, 2004·Infection and Immunity·Arturo Casadevall, Liise-anne Pirofski
Mar 23, 2005·FEMS Immunology and Medical Microbiology·Ken-Ichi IshibashiNaohito Ohno
Jun 28, 2005·Current Molecular Medicine·J E Cutler
Sep 9, 2005·The Journal of Experimental Medicine·Antonella TorosantucciAntonio Cassone
Oct 6, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Scott K Fridkin
Nov 29, 2005·Trends in Molecular Medicine·Arturo Casadevall, Liise-Anne Pirofski

❮ Previous
Next ❯

Citations

Aug 13, 2011·Clinical and Vaccine Immunology : CVI·Hong Xin, Jim E Cutler
Jul 24, 2013·Clinical & Developmental Immunology·Francesca BugliFrancesco Paroni Sterbini
Jan 1, 2013·ISRN Preventive Medicine·M Anaul Kabir, Zulfiqar Ahmad
Oct 29, 2011·Methods : a Companion to Methods in Enzymology·B Vijayalakshmi AyyarRichard O'Kennedy
Apr 9, 2011·New Biotechnology·Jody D Berry, Ryan G Gaudet
Jun 22, 2012·Expert Opinion on Pharmacotherapy·Tzi Bun NgJack Ho Wong
Mar 15, 2011·FEMS Microbiology Letters·Edina K Szabo, Donna M MacCallum
Jun 17, 2016·Cellular Microbiology·Ema PaulovičováNikolay E Nifantiev
Jun 22, 2017·Preparative Biochemistry & Biotechnology·Zhihua WuHongbing Chen
Jan 11, 2019·Frontiers in Immunology·Sigifredo Pedraza-SánchezMartha Torres
Mar 23, 2021·International Immunopharmacology·R Diez-OrejasM T Portolés

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Related Papers

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Kerry ChesterRichard Begent
Analytical and Bioanalytical Chemistry
Maria G E G BremerWillem Haasnoot
© 2021 Meta ULC. All rights reserved